Robert W. Baird lowered shares of Nivalis Therapeutics Inc. (NASDAQ:NVLS) from an outperform rating to a neutral rating in a research report released on Tuesday. The firm currently has $3.00 price target on the stock, down from their previous price target of $29.00.

A number of other research analysts also recently issued reports on the stock. Raymond James Financial Inc. initiated coverage on shares of Nivalis Therapeutics in a research report on Tuesday, September 13th. They issued an outperform rating and a $20.00 price objective on the stock. Stifel Nicolaus downgraded shares of Nivalis Therapeutics from a buy rating to a hold rating and cut their price objective for the stock from $16.00 to $3.25 in a research report on Tuesday. Piper Jaffray Cos. reaffirmed a buy rating and issued a $16.00 price objective on shares of Nivalis Therapeutics in a research report on Tuesday, August 30th. HC Wainwright reaffirmed a buy rating on shares of Nivalis Therapeutics in a research report on Monday, August 8th. Finally, Zacks Investment Research raised shares of Nivalis Therapeutics from a sell rating to a buy rating and set a $8.50 price objective on the stock in a research report on Thursday, October 20th. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company presently has an average rating of Hold and an average price target of $9.00.

Nivalis Therapeutics (NASDAQ:NVLS) opened at 2.57 on Tuesday. Nivalis Therapeutics has a 12 month low of $3.68 and a 12 month high of $9.45. The company’s market cap is $39.95 million. The company’s 50-day moving average is $6.46 and its 200-day moving average is $5.84.

Nivalis Therapeutics (NASDAQ:NVLS) last issued its quarterly earnings data on Monday, November 7th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.11. On average, equities research analysts expect that Nivalis Therapeutics will post ($2.10) EPS for the current fiscal year.

WARNING: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2016/11/30/nivalis-therapeutics-inc-nvls-downgraded-to-neutral-at-robert-w-baird.html.

In other Nivalis Therapeutics news, EVP David Malcom Rodman sold 5,820 shares of Nivalis Therapeutics stock in a transaction that occurred on Tuesday, October 4th. The shares were sold at an average price of $7.96, for a total transaction of $46,327.20. Following the completion of the sale, the executive vice president now directly owns 18,056 shares in the company, valued at approximately $143,725.76. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 3.00% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. Paloma Partners Management Co acquired a new stake in shares of Nivalis Therapeutics during the second quarter valued at approximately $105,000. Bank of New York Mellon Corp boosted its stake in shares of Nivalis Therapeutics by 7.8% in the third quarter. Bank of New York Mellon Corp now owns 16,494 shares of the company’s stock valued at $134,000 after buying an additional 1,189 shares during the last quarter. Spark Investment Management LLC acquired a new stake in shares of Nivalis Therapeutics during the third quarter valued at approximately $145,000. Endurant Capital Management LP boosted its stake in shares of Nivalis Therapeutics by 29.8% in the third quarter. Endurant Capital Management LP now owns 85,412 shares of the company’s stock valued at $694,000 after buying an additional 19,629 shares during the last quarter. Finally, Opaleye Management Inc. boosted its stake in shares of Nivalis Therapeutics by 160.0% in the second quarter. Opaleye Management Inc. now owns 260,000 shares of the company’s stock valued at $1,287,000 after buying an additional 160,000 shares during the last quarter. Institutional investors and hedge funds own 79.26% of the company’s stock.

Nivalis Therapeutics Company Profile

Nivalis Therapeutics, Inc is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.

5 Day Chart for NASDAQ:NVLS

Receive News & Stock Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related stocks with our FREE daily email newsletter.